Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.158
Neutral
RSI(14)
42.303
Neutral
STOCH(KDJ)(9,3,3)
56.638
Neutral
ATR(14)
0.478
Low Volatility
CCI(14)
75.722
Neutral
Williams %R
32.819
Buy
TRIX(12,20)
-0.644
Sell
StochRSI(14)
88.047
Buy
Embecta Corp
EMBC12.080USD
+0.160+1.34%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
706.63MMarket Cap
7.38P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Embecta Corp
Currency: USD Updated: 2025-12-23Key Insights
Embecta Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 54/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 16.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Embecta Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
16.667
Target Price
+50.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Embecta Corp Highlights
StrengthsRisks
Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.08B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 38.36%.
Undervalued
The company’s latest PE is 7.29, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.75M shares, decreasing 0.01% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 1.05K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-23The current financial score of Embecta Corp is 9.07, ranking 14/208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 264.00M, representing a year-over-year decrease of 7.72%, while its net profit experienced a year-over-year decrease of 80.82%.
Score
Financials
6.80
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
9.95
Growth Potential
9.08
Shareholder Returns
9.52
Embecta Corp's Company Valuation
Currency: USD Updated: 2025-12-23The current valuation score of Embecta Corp is 5.97, ranking 182/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 7.29, which is 245.63% below the recent high of 25.18 and 8.50% above the recent low of 6.67.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 54/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-23The current earnings forecast score of Embecta Corp is 6.50, ranking 171/208 in the Healthcare Equipment & Supplies industry. The average price target for Embecta Corp is 14.00, with a high of 25.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Hold
Current Rating
16.667
Target Price
+50.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Embecta Corp
EMBC
4
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-23The current price momentum score of Embecta Corp is 6.64, ranking 122/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 14.13 and the support level at 10.36, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.824
Buy
MA10
11.823
Buy
MA20
11.958
Buy
MA50
13.172
Sell
MA100
13.528
Sell
MA200
12.437
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-23The current institutional shareholding score of Embecta Corp is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 107.09%, representing a quarter-over-quarter decrease of 2.99%. The largest institutional shareholder is The Vanguard, holding a total of 5.38M shares, representing 9.08% of shares outstanding, with 20.47% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
American Century Investment Management, Inc.
River Road Asset Management, LLC
Deerfield Management Company, L.P.
State Street Investment Management (US)
Jefferies LLC
William Blair Investment Management, LLC
Millennium Management LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-23The current risk assessment score of Embecta Corp is 6.90, ranking 50/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.07
VaR
--
240-Day Maximum Drawdown
+54.17%
240-Day Volatility
+56.44%
Return
Best Daily Return
60 days
+6.12%
120 days
+18.53%
5 years
--
Worst Daily Return
60 days
-7.44%
120 days
-7.62%
5 years
--
Sharpe Ratio
60 days
-1.37
120 days
+0.86
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+54.17%
3 years
+71.68%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.76
3 years
-0.26
5 years
--
Skewness
240 days
+0.33
3 years
+2.46
5 years
--
Volatility
Realised Volatility
240 days
+56.44%
5 years
--
Standardised True Range
240 days
+5.20%
5 years
--
Downside Risk-Adjusted Return
120 days
+148.95%
240 days
+148.95%
Maximum Daily Upside Volatility
60 days
+26.47%
Maximum Daily Downside Volatility
60 days
+33.42%
Liquidity
Average Turnover Rate
60 days
+1.13%
120 days
+1.10%
5 years
--
Turnover Deviation
20 days
+36.27%
60 days
+30.85%
120 days
+28.05%
Peer Comparison
Healthcare Equipment & Supplies
Embecta Corp
EMBC
7.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
UFP Technologies Inc
UFPT
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Embecta Corp?
The TradingKey Stock Score provides a comprehensive assessment of Embecta Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Embecta Corp’s performance and outlook.
How do we generate the financial health score of Embecta Corp?
To generate the financial health score of Embecta Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Embecta Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Embecta Corp.
How do we generate the company valuation score of Embecta Corp?
To generate the company valuation score of Embecta Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Embecta Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Embecta Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Embecta Corp.
How do we generate the earnings forecast score of Embecta Corp?
To calculate the earnings forecast score of Embecta Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Embecta Corp’s future.
How do we generate the price momentum score of Embecta Corp?
When generating the price momentum score for Embecta Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Embecta Corp’s prices. A higher score indicates a more stable short-term price trend for Embecta Corp.
How do we generate the institutional confidence score of Embecta Corp?
To generate the institutional confidence score of Embecta Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Embecta Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Embecta Corp.
How do we generate the risk management score of Embecta Corp?
To assess the risk management score of Embecta Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Embecta Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Embecta Corp.
